JPS605569B2 - Treatment adhesive tape or sheet - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a therapeutic post-applying tape or sheet suitable for treating skin diseases, anti-inflammation, analgesia, and the like.

In order to absorb drugs into the ridges of the skin, by increasing the water content of the stratum corneum, not only the hair follicle-sebaceous system but also the absorption path that passes directly through the stratum corneum can be used, allowing effective drug absorption. . For this reason, occlusive bandage therapy (ODT therapy) has recently become popular for the treatment of skin diseases and the like.

This involves applying an external medicine such as an ointment to the skin and covering it with an impermeable film to ensure effective absorption of the medicine. However, this occlusive bandage therapy is not only troublesome to apply to the affected area, but also bulky, easy to peel off, and difficult to adhere to the affected area when the area of the affected area is large or the shape of the affected area is complex. There were some drawbacks, such as poor performance. In order to eliminate these drawbacks, therapeutic adhesive tapes are commercially available in which a sensitive adhesive containing a drug is coated on one side of a base film.

However, such therapeutic adhesive tapes generally do not adhere to the skin.
Although the tape is applied for between 1 and 2 hours, more than 60% of the drug remains in the tape without being absorbed into the skin, resulting in a much larger amount of drug being applied to the pressure-sensitive adhesive layer than is necessary for treatment. This was not economical. An object of the present invention is to improve the above-mentioned drawbacks and to provide an economical adhesive tape or sheet for medical treatment with high efficiency in the absorption of drugs into the skin.

In order to increase the absorption efficiency of the drug into the skin, it is possible to apply the drug directly onto the pressure-sensitive adhesive layer of the therapeutic adhesive tape without including the drug in the pressure-sensitive adhesive layer.
In that case, the adhesiveness of the pressure-sensitive adhesive layer is increased by the chemicals, causing problems such as the tape coming off during use.

As a result of various studies, the present inventors have found that by laminating a pressure-sensitive adhesive layer that does not contain a drug and a pressure-sensitive adhesive layer that contains a drug on a base film, the adhesiveness to the skin is impaired. The drug is efficiently absorbed into the skin without
That is, we have found that the same therapeutic effect can be obtained with a smaller amount of drug than in the case of a single layer of conventional pressure-sensitive adhesive containing a drug.

The gist of the present invention is that a pressure-sensitive adhesive layer that does not contain a drug is provided on one side of a base film, and a pressure-sensitive adhesive layer that contains a drug is provided on the pressure-sensitive adhesive layer. The therapeutic adhesive tape or sheet is characterized in that the total thickness of the pressure-sensitive adhesive layers is between 20 and 100 microns.

The base film used in the present invention includes polyethylene, polypropylene, ethylene-vinyl acetate copolymer,
A flexible film such as European polypinyl chloride or cellophane is preferably used.

The thickness of the base film is preferably in the range of 50 to 100 microns. Pressure-sensitive adhesives used in the present invention include rubber-based pressure-sensitive adhesives prepared by adding tackifying resins, softeners, etc. to natural rubber, isoprene rubber, styrene-butadiene rubber, etc., acrylic acid alkyl esters, methacrylic acid Acrylic pressure-sensitive adhesives made of copolymers mainly composed of alkyl esters (preferably the number of carbon atoms in the alkyl group is 4 to 12), silicone-based, urethane-based, etc.
Pressure-sensitive adhesives such as polyvinyl ether and polyisobutylene are preferably used.

- As the drugs used in the present invention, hydrocortisone, hydrocortisone acetate, adrenal cortical hormones such as prednisolone, dexamethasone, betamethasone, anti-inflammatory agents, antihistamines, bactericidal agents, etc. are used as appropriate depending on the purpose.

In the present invention, a pressure-sensitive adhesive layer containing no drug is provided on one side of the Motomura film, and a pressure-sensitive adhesive layer containing a drug is provided on the pressure-sensitive adhesive layer.

The manufacturing method is to apply a pressure-sensitive adhesive that does not contain a drug on the Motomura film and then apply a pressure-sensitive adhesive mixed with a drug on top of that, or to apply a pressure-sensitive adhesive mixed with a drug on a release paper. A method of coating and transferring this onto a base film coated with a pressure-sensitive adhesive that does not contain chemicals, 3 pressure-sensitive adhesives that contain chemicals on release paper, and pressure-sensitive adhesives that do not contain chemicals. A method of applying the agent in order and transferring it onto the base film is appropriately employed. The combined thickness of the pressure-sensitive adhesive layer not containing a drug and the pressure-sensitive adhesive layer containing a drug is in the range of 20 to 100 microns.

If the pressure-sensitive adhesive layer is too thin, it will not have sufficient adhesion to the skin.If the pressure-sensitive adhesive layer is too thick, it will not be economical. The amount of adhesive varies depending on the type of drug, its content, the rate of absorption into the skin, etc., and should be determined appropriately taking these into consideration, but it is preferably thinner than a pressure-sensitive post-adhesive layer that does not contain a drug.Therapeutic adhesive When the tape or sheet contains the same amount of drug per unit area, the thinner the pressure-sensitive adhesive layer containing the drug, the faster the drug will be absorbed into the skin and the greater the amount absorbed.

That is, as the thickness of the pressure-sensitive adhesive layer containing the drug is reduced, the same therapeutic effect can be obtained with a smaller amount of the drug. however,
Care must be taken because if the concentration of the drug in the pressure-sensitive adhesive layer containing the drug becomes too high, the adhesion to the skin will decrease. The amount of the drug in the pressure-sensitive adhesive layer containing the drug varies depending on the thickness of the adhesive layer, adhesion to the skin, type of drug, etc., but is preferably in the range of about 1 to 100 parts per part. .

The pressure-sensitive adhesives in the pressure-sensitive adhesive layer not containing a drug and the pressure-sensitive adhesive layer containing a drug may be the same or different.

When the therapeutic adhesive tape or sheet of the present invention is applied to the affected area of the skin, the moisture content of the skin increases and the drug is absorbed transdermally. At this time, since the drug is present in the pressure-sensitive adhesive layer on the side of the therapeutic tape or sheet closer to the skin, the drug is efficiently absorbed transdermally. Since the therapeutic adhesive tape or sheet of the present invention is constructed as described above, it is economical and has good drug absorption efficiency into the skin.

The therapeutic adhesive tape or sheet of the present invention can be used to treat various skin diseases such as psoriasis vulgaris, chronic eczema, Vidal moss lamp, progressive palmar keratoderma, and other anti-inflammatory and analgesic treatments by changing the type of drug. It can be used as appropriate.

The present invention will be explained below with reference to Examples.

Example 1 Ethyl acetate 6 parts by weight 2
- Ethylhexyl acrylate 30 parts by weight Maleic anhydride 1.5 parts by weight Styrene
145 parts by weight Penzoyl peroxide 0.1 parts by weight The above composition was placed in a reaction vessel and polymerized for 2 hours at 80 oo in a nitrogen stream to obtain a pressure-sensitive adhesive solution.

After applying this pressure-sensitive adhesive solution onto a base film (a corona discharge-treated ethylene-vinyl acetate copolymer film with a thickness of 70 mm), the pressure-sensitive adhesive layer is 40 mm thick. It was dried for 1 hour at 70:00.

Next, dissolve 100 parts of the above pressure-sensitive adhesive solution and 30 parts of the 2 wt% methanol solution of prednisolone, apply this onto release paper so that the pressure-sensitive adhesive layer has a thickness of 20A, and then apply the mixture at 70QO for 10 minutes. After drying, this prednisolone-containing pressure-sensitive adhesive layer was superimposed and transferred onto the pressure-sensitive adhesive layer of the base film to obtain a therapeutic adhesive tape.

Example 2 Pressure Sensitive Adhesive Solution 100% of Prednisolone 2% by Weight
An adhesive tape for bran was obtained in the same manner as in Example 1, except that 60 mm of methanol solution was dissolved and this was applied onto a release paper so that the pressure-sensitive adhesive layer was 10 mm thick.

Example 3 ** 100% pressure-sensitive adhesive solution and 30% prednisolone 2% by weight methanol solution were dissolved and applied onto template paper so that the pressure-sensitive adhesive layer was 10% thick. A therapeutic adhesive tape was obtained in the same manner as in Example 1.

Comparative Example 100 g of the pressure-sensitive adhesive solution obtained in Example 1 and 10 g of the 2 wt% methanol solution of donizolone were dissolved, and this was applied to a pressure-sensitive adhesive layer on a base film (same as in Example 1). After applying it so that the thickness of
After drying for a minute, a therapeutic adhesive tape was obtained.

Prednisolone remaining on the tape after applying the therapeutic adhesive tapes obtained in Examples 1, 2, 3 and Comparative Examples and stored indoors in a container for one month after their respective preparations to the skin for 24 days. was quantified, and the amount of prednisolone absorbed into the skin was calculated.

The results are shown in Table 1.

Table 1 From Table 1, it can be seen that the therapeutic adhesive tapes of Examples 1 and 2 have the same prednisolone content as the comparative example, but the absorbed amount is larger, and that of Example 3 is 1/2 that of the comparative example. It can be seen that the absorption amount is almost the same as that of the comparative example with a prednisolone content of .

Claims (1)

[Scope of Claims] 1. A pressure-sensitive adhesive layer not containing a drug is provided on one side of a base film, and a pressure-sensitive adhesive layer containing a drug is provided on the pressure-sensitive adhesive layer, A therapeutic adhesive tape or sheet, characterized in that the total thickness of the pressure-sensitive adhesive layers is between 20 and 100 microns. 2 Claim 1 in which the drug is an adrenocortical hormone
Therapeutic adhesive tape or sheet described in Section 1.